Oppenheimer assumed coverage of Cue Biopharma with an Outperform rating and $10 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CUE:
- Cue Biopharma to host conference call
- Cue Biopharma to present at FOCIS 2023 annual meeting
- Cue Biopharma to Host Investor Call
- Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
- Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting